These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

356 related items for PubMed ID: 19744284

  • 1. Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study.
    Viganò M, Dengler T, Mattei MF, Poncelet A, Vanhaecke J, Vermes E, Kleinloog R, Li Y, Gezahegen Y, Delgado JF, RAD A2411 Study Investigators.
    Transpl Infect Dis; 2010 Feb; 12(1):23-30. PubMed ID: 19744284
    [Abstract] [Full Text] [Related]

  • 2. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients.
    Lehmkuhl HB, Arizon J, Viganò M, Almenar L, Gerosa G, Maccherini M, Varnous S, Musumeci F, Hexham JM, Mange KC, Livi U, 2411 Study Investigators.
    Transplantation; 2009 Jul 15; 88(1):115-22. PubMed ID: 19584690
    [Abstract] [Full Text] [Related]

  • 3. Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation.
    Kobashigawa J, Ross H, Bara C, Delgado JF, Dengler T, Lehmkuhl HB, Wang SS, Dong G, Witte S, Junge G, Potena L.
    Transpl Infect Dis; 2013 Apr 15; 15(2):150-62. PubMed ID: 23013440
    [Abstract] [Full Text] [Related]

  • 4. A 1-year randomized controlled study of everolimus versus mycophenolate mofetil with reduced-dose cyclosporine in maintenance heart transplant recipients.
    Bara C, Dengler T, Hack MA, Ladenburger S, Lehmkuhl HB.
    Transplant Proc; 2013 Apr 15; 45(6):2387-92. PubMed ID: 23953553
    [Abstract] [Full Text] [Related]

  • 5. Cyclosporine lowering with everolimus versus mycophenolate mofetil in heart transplant recipients: long-term follow-up of the SHIRAKISS randomized, prospective study.
    Potena L, Prestinenzi P, Bianchi IG, Masetti M, Romani P, Magnani G, Fallani F, Coccolo F, Russo A, Ponticelli C, Rapezzi C, Grigioni F, Branzi A.
    J Heart Lung Transplant; 2012 Jun 15; 31(6):565-70. PubMed ID: 22341702
    [Abstract] [Full Text] [Related]

  • 6. A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus.
    Hill JA, Hummel M, Starling RC, Kobashigawa JA, Perrone SV, Arizón JM, Simonsen S, Abeywickrama KH, Bara C.
    Transplantation; 2007 Dec 15; 84(11):1436-42. PubMed ID: 18091519
    [Abstract] [Full Text] [Related]

  • 7. Impact of de novo everolimus-based immunosuppression on incisional complications in heart transplantation.
    Zuckermann A, Arizon JM, Dong G, Eisen HJ, Kobashigawa J, Lehmkuhl H, Ross H, Pelligrini C, Wang SS, Barten MJ.
    Transplantation; 2011 Sep 15; 92(5):594-600. PubMed ID: 21862955
    [Abstract] [Full Text] [Related]

  • 8. Cytomegalovirus risk factors in renal transplantation with modern immunosuppression.
    Bataille S, Moal V, Gaudart J, Indreies M, Purgus R, Dussol B, Zandotti C, Berland Y, Vacher-Coponat H.
    Transpl Infect Dis; 2010 Dec 15; 12(6):480-8. PubMed ID: 20629971
    [Abstract] [Full Text] [Related]

  • 9. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients.
    Vítko S, Margreiter R, Weimar W, Dantal J, Viljoen HG, Li Y, Jappe A, Cretin N, RAD B201 Study Group.
    Transplantation; 2004 Nov 27; 78(10):1532-40. PubMed ID: 15599319
    [Abstract] [Full Text] [Related]

  • 10. CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A.
    Abou-Ayache R, Büchler M, Lepogamp P, Westeel PF, Le Meur Y, Etienne I, Lobbedez T, Toupance O, Caillard S, Goujon JM, Bergougnoux L, Touchard G.
    Nephrol Dial Transplant; 2008 Jun 27; 23(6):2024-32. PubMed ID: 18199693
    [Abstract] [Full Text] [Related]

  • 11. Cardiac allograft vasculopathy by intravascular ultrasound in heart transplant patients: substudy from the Everolimus versus mycophenolate mofetil randomized, multicenter trial.
    Kobashigawa JA, Pauly DF, Starling RC, Eisen H, Ross H, Wang SS, Cantin B, Hill JA, Lopez P, Dong G, Nicholls SJ, A2310 IVUS Substudy Investigators.
    JACC Heart Fail; 2013 Oct 27; 1(5):389-99. PubMed ID: 24621971
    [Abstract] [Full Text] [Related]

  • 12. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
    Santos SM, Carlos CM, Cabanayan-Casasola CB, Danguilan RA.
    Transplant Proc; 2012 Jan 27; 44(1):154-60. PubMed ID: 22310603
    [Abstract] [Full Text] [Related]

  • 13. Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial.
    Eisen HJ, Kobashigawa J, Starling RC, Pauly DF, Kfoury A, Ross H, Wang SS, Cantin B, Van Bakel A, Ewald G, Hirt S, Lehmkuhl H, Keogh A, Rinaldi M, Potena L, Zuckermann A, Dong G, Cornu-Artis C, Lopez P.
    Am J Transplant; 2013 May 27; 13(5):1203-16. PubMed ID: 23433101
    [Abstract] [Full Text] [Related]

  • 14. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study.
    Lorber MI, Mulgaonkar S, Butt KM, Elkhammas E, Mendez R, Rajagopalan PR, Kahan B, Sollinger H, Li Y, Cretin N, Tedesco H, B251 Study Group.
    Transplantation; 2005 Jul 27; 80(2):244-52. PubMed ID: 16041270
    [Abstract] [Full Text] [Related]

  • 15. Heart transplantation under cyclosporine or tacrolimus combined with mycophenolate mofetil or everolimus.
    Wang SS, Chou NK, Chi NH, Wu IH, Chen YS, Yu HY, Huang SC, Wang CH, Ko WJ, Tsao CI, Sun CD.
    Transplant Proc; 2008 Oct 27; 40(8):2607-8. PubMed ID: 18929814
    [Abstract] [Full Text] [Related]

  • 16. 5-year follow-up of a randomized clinical study comparing everolimus plus reduced-dose cyclosporine with mycophenolate mofetil plus standard-dose cyclosporine in de novo kidney transplantation: Retrospective single center assessment.
    Hiramitsu T, Okada M, Futamura K, Yamamoto T, Tsujita M, Goto N, Narumi S, Watarai Y, Takeda A, Iwasaki K, Uchida K, Kobayashi T.
    Int Immunopharmacol; 2016 Oct 27; 39():192-198. PubMed ID: 27491025
    [Abstract] [Full Text] [Related]

  • 17. Incidence of leukopenia and cytomegalovirus disease in kidney transplants treated with mycophenolate mofetil combined with low cyclosporine and steroid doses.
    Moreso F, Serón D, Morales JM, Cruzado JM, Gil-Vernet S, Pérez JL, Fulladosa X, Andrés A, Grinyó JM.
    Clin Transplant; 1998 Jun 27; 12(3):198-205. PubMed ID: 9642510
    [Abstract] [Full Text] [Related]

  • 18. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
    Favi E, Citterio F, Spagnoletti G, Gargiulo A, Delreno F, Romagnoli J, Castagneto M.
    Transplant Proc; 2009 May 27; 41(4):1152-5. PubMed ID: 19460503
    [Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
    Oh CK, Huh KH, Ha J, Kim YH, Kim YL, Kim YS.
    Transplantation; 2015 Jan 27; 99(1):180-6. PubMed ID: 24983307
    [Abstract] [Full Text] [Related]

  • 20. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients.
    Vítko S, Margreiter R, Weimar W, Dantal J, Kuypers D, Winkler M, Øyen O, Viljoen HG, Filiptsev P, Sadek S, Li Y, Cretin N, Budde K, RAD B201 Study Group.
    Am J Transplant; 2005 Oct 27; 5(10):2521-30. PubMed ID: 16162203
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.